Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma
Abstract For locally advanced intrahepatic cholangiocarcinoma (ICC), the combination of cisplatin plus gemcitabine (CisGem) is the standard first-line treatment. However, the outcome remains unsatisfied with the median overall survival (OS) of 11.7 months. We aimed to compare the effect of CisGem re...
Saved in:
| Main Authors: | Lin Liu, Huanhuan Wang, Liang Sun, Yufang Liu, Yujing Zhang, Xutian Wang, Xin Zheng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-09586-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
by: Masashi Tsunematsu, et al.
Published: (2019-06-01) -
Adjuvant Gemcitabine-cisplatin Combination for Biliary Tract Cancer: A Real Life Experience
by: Fatih Kuş, et al.
Published: (2025-08-01) -
Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Qingyu Xu, et al.
Published: (2025-05-01) -
Hepatic arterial infusion chemotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a meta-analysis of survival outcomes
by: Di Zeng, et al.
Published: (2025-07-01) -
Postoperative adjuvant hepatic arterial infusion chemotherapy with gemcitabine-cisplatin sequential capecitabine combined with PDL1 inhibitors in resected high-risk intrahepatic cholangiocarcinom: study protocol for a prospective, multicenter, single-arm, phase 2 trial (HgcCP trial)
by: Ying Yang, et al.
Published: (2025-07-01)